Special Report Japanese Healthcare Expansion in India



Expanding Operations & Investments in India



Confidential May 2025

27 Japanese healthcare companies have commercial and/or manufacturing presence in India

Active Japanese Healthcare Companies in India

Medical Devices Pharmaceutical Products 7.69 N = 1782.4%

With only Commercial

presence in India

sector participation is nascent but

 Firms typically establish local subsidiaries, branch offices, or regional headquarters.


companies operate in India; healthcare

As of 2024, over 1,450 Japanese

growing.


India's PLI schemes and stronger Japan-India relations promote manufacturing expansion and business opportunities.







In manufacturing, they have cover in diagnostics, molecular biology, and biopharma services, alongside key pharmaceutical segments



🗰 aranca

Source: List of Japanese enterprises JICA, Japanese Business Establishments in India JETRO, Country report on international medical development, Aranca Analysis

Japanese Medical Device Companies with Direct Commercial Presence in India

Medical equipment and high-tech solution companies generally maintain a commercial presence

	Established in	Revenue (in USD Mn)					
Company Name		2020	2021	2022	2023	2024	CAGR (20-24)
Shimadzu Medical (India) Pvt. Ltd.	2001						
CBC Corporation India	2005			20.26	23.47		
Fujifilm India Pvt. Ltd.	2007						
Astellas Pharma India Private Limited	2008	5.07	4.59	5.97	3.8	5.28	1.0%
A&D Instruments India Pvt. Ltd.	2008	15.72	17.61	30.7	36.08	34.35	21.6%
Mitsubishi Chemical India	2008	8.31	6.85	8.93	8.37	9.76	4.1%
Omron Healthcare	2010	17.69	29.13	32.18	32.61	27.8	12.0%
Olympus Corporation Services India	2010	57.52	39.9	51.83	64.75	79.99	8.6%
Nipro Medical India	2010	47.9	29.51	35.97	47.91	56.47	4.2%
Konica Minolta Healthcare India Pvt. Ltd	2010	24.14	23.35	34.07	34.59		
Nihon kohden india pvt. Itd.	2011	18.92	16.9	37.91	30.4	26.59	8.9%
PENTAX Medical India	2012	6.29	4.98	6.08	6.14	4.95	-5.8%
Terumo India	2013						
ASAHI INTECC CO., LTD	2014						
Tosoh India	2015	42.19	40.37	61.89	55.82	73.22	14.8%
Mani Medical India	2017	3.6	3.54	5.9	7.18	8.19	22.8%
Canon Medical Systems India Pvt., Ltd.	2023						

Source: List of Japanese enterprises JICA, Japanese Business Establishments in India JETRO, Aranca Analysis

Japanese Pharmaceutical Companies with Direct Commercial Presence in India

Pharma companies & CMOs often establish manufacturing facilities for cost advantages


Company Name	Established in	Revenue (in USD Mn)					
Company Name	Established III	2020	2021	2022	2023	2024	CAGR (20-24)
Sysmex India	1998	24.19					
Eisai pharmaceuticals	2004	94.59	66.65	63.18	68.82	57.09	-11.9%
Horiba India	2006	35.79	33.41	50.74	54.62	59.16	13.4%
Arkray Healthcare Pvt Ltd	2007	15.00	20.38	25.17	23.35		
Meiji Seika Pharma (Medreich)	2011	170.01	181.65	191.26	199.26	209.82	
DSS Takara Bio India	2011	6.24	9.25	7.94	4.79		
Ajinomoto Bio-Pharma Services India Pvt. Ltd	2011	16.27	7.84	23.84	14.08	23.3	9.4%
Takeda pharmaceuticals India	2011	76.02	65.48	73.57	68.82	94.28	5.5%
Otsuka Pharmaceutical India Private Limited	2012	45.78	63.6	69.38	77.99		
SUNWAYS ROHTO PRIVATE LIMITED	2013						

Source: List of Japanese enterprises JICA, Japanese Business Establishments in India JETRO, Aranca Analysis



Japanese Companies Overseas Expansion Sentiments

JETRO: ~81% Japanese firms prefer expansion in India, reflecting strong business confidence



Source: List of Japanese enterprises JICA, Japanese Business Establishments in India JETRO, Aranca Analysis

maranca

Rapid digitization and local production growth, driven by government initiatives has been observed..

Digitization and use of Al to drive innovation and efficiency	AI/ML is revolutionizing India's healthcare sector, fostering innovation in diagnostics (Qure.ai), telemedicine (Practo), and supply chain management (MediBuddy). Government initiatives like NITI Aayog's AI strategy are driving adoption, with the healthtech market rapidly integrating AI and ML for growth.
Leveraging India's growing technological and scientific expertise	Top pharma companies such as Novartis and AstraZeneca are leveraging Indian facilities for drug discovery, clinical trials, and AI-driven R&D. Government-backed medical and pharma parks such as Hyderabad Pharma City are boosting local manufacturing and driving innovation.
Global pharma and med-tech hub	India is emerging as a key destination for pharma outsourcing, driven by cost efficiency, a skilled workforce, and reduced reliance on China. With CDMO, API, and biosimilars production expanding, companies such as Biocon, Syngene, and Dr. Reddy's are leading the charge.
Innovation driven by government policies	India's healthcare sector is driven by government policies such as Production-Linked Incentive (PLI) scheme that is promoting API production, Ayushman Bharat Digital Mission (ABDM) which aims to digitize healthcare through United Health Interface and electronic Health records and boosting MedTech startups by providing funding.
Shift towards Consumer-centric innovation	With most of Indian consumers prioritizing convenience and quality, India's healthtech market is evolving with rising digital adoption, preventive health focus, and AI-driven personalization especially after COVID-19.

Source: Company Websites. Industry Reports, Aranca Analysis



Current Market Size and Projected Growth of Indian Healthcare Sector

..leading to \$198 Bn healthcare sector of India, expected to grow at ~12.7% CAGR, to \$320Bn by 2028

\$105 Bn \$58 Bn \$11 Bn \$10 Bn \$16 Bn CAGR: 12.7% -> 320.0 **Diagnostics and** Pharma IT Import other (78%) (13%) (50%) 198.0 Outpatient consultation (10%) **Retail pharma** (15%) CRO (10%) Domestic Hospitals (22%) CDMO (25%) (72%) Providers Pharma Medical 2024 2028E Pharma Insurance services Devices

Source: India Brand Equity Foundation, HealthQuad | Bain & Company, Inc., Healthcare innovation in India Report, Aranca Analysis



5 Special Report: Japanese Healthcare Expansion in India | May 2025


2024-2028| Figures in \$ Billion

Indian Healthcare Market Size Growth

[🖷] aranca

PE/VC funding for Healthcare Innovation in India

Deal value has remained consistent, but average value per deal has grown, with 2022 being an outlier



The average deal value has grown over the years, with investments remaining steady. However, 2022 saw a sharp rise due to five PharmEasy investments totaling \$1.5B.

Source: India Brand Equity Foundation, HealthQuad | Bain & Company, Inc. Healthcare innovation in India, Aranca Analysis

*Includes PE/VC, grants, and debt-equity activities **2024 includes values of first three quarters

6 Special Report: Japanese Healthcare Expansion in India | May 2025

Japanese firms have significant activity across major investment themes in India's healthcare sector

Key Themes	Overview	Examples of investments by Japanese firms
Retail pharmacies going digital	E-pharmacy startups are innovating with online medicine delivery and Al-powered prescriptions, while traditional pharmacies adopt digital solutions to enhance customer convenience.	PharmEasy, an online drug delivery platform has raised \$0.21 billion of venture funding with one of the active investors being Dream Incubator.
Rise of Digital health and wellness	The surge in digital adoption, which accelerated during the pandemic, continues with investments in telehealth and e-consultations.	Companies such as Medikabazaar, a B2B platform for the procurement of medical supplies – has received funding from Rebright partners, a Japanese Venture Capital.
Technological improvements to support operational efficiencies	Efforts to digitize healthcare and streamline the supply chain have attracted investors, especially in enterprise solutions improving efficiency and market scalability.	Saveo pharmaceutical distribution platform designed for the procurement of medicines and related supplies for pharmacies – has received funding from several Japanese investors namely: Gunosy Capital, ICMG Partners, and Incubate Fund Asia
Investments supporting Diversification and adjacencies in the space	India's healthcare sector is seeing rising investments and pharma diversification. Pharma giants such as Sun Pharma and Cipla have invested in companies such as Agatsa software, a med-tech company and Achira Labs, a microfluidics-based medical diagnostics company.	While Japanese companies have not made any such investments – this represents a strong opportunity, wherein pharmaceutical firms could benefit from investing in India's expanding MedTech, diagnostics, and digital health sectors.
Late-stage investments driven by government initiatives	Government-backed localization in healthcare has boosted expertise among Indian pharma players, attracting investor funding and government investments.	Emcure Pharmaceuticals, a pharmaceutical manufacturer from India has received funding from Nomura Holdings.

Source: HealthQuad | Bain & Company, Inc. Healthcare innovation in India, Aranca Analysis



500+ Strong team of professionals across multi-disciplinary domains 2500+ Global clients

120+ Sectors and sub-sectors researched by our analysts 80+ Countries where we have delivered projects

aranca

ABOUT ARANCA



Growth Advisory CXOs in Strategy, SBUs, Sales, Marketing, CI/MI, Innovation



Technology | IP Research & Advisory

R&D, Tech Scouting, Open Innovation, IP Teams, Product Development



Valuation & Financial Advisory

CFOs in Start-ups, PE/VC Firms, Corporate M&A Teams, Mid-market Companies



Investment Research & Analytics

Brokerage, Hedge Funds, IRPs, I-Banks, AMCs, Investor Relations



Vibin Theril Associate Vice President – Growth Advisory

> +91 9819350761 vibin.theril@aranca.com



Kartikeya Rao

Engagement Lead – Growth Advisory

+91 9022654622 kartikeya.rao@aranca.com



Vasuda Venkitakrishnan

Engagement Lead – Growth Advisory

+91 9820967433 vasuda.v@aranca.com



Decide Fearlessly

From startups to the Fortune 500, private equity and global financial firms, Aranca is the trusted research and advisory partner for over 2500 companies

www.aranca.com

Haranca

This material is exclusive property of Aranca. No part of this presentation may be used, shared, modified and/or disseminated without permission. All rights reserved.